Hepatic toll-like receptor 4 expression is associated with portal inflammation and fibrosis in patients with NAFLD

Liver International

Volumn 35, Issue 2, 2015, Pages 569-581

  Vespasiani Gentilucci, Umberto ^a   Carotti, Simone ^a   Perrone, Giuseppe ^a   Mazzarelli, Chiara ^a   Galati, Giovanni ^a   Onetti Muda, Andrea ^a   Picardi, Antonio ^a   Morini, Sergio ^a  

^a UNIVERSITY CAMPUS BIO MEDICO   (Italy)

Author keywords

Ductular reaction; Fibrosis; Hepatic progenitor cells; Hepatic stellate cells; Lipopolysaccharides; Myofibroblast; Portal inflammation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANTIDIABETIC AGENT; ANTIHYPERTENSIVE AGENT; CD68 ANTIGEN; CYTOKERATIN 7; LIPOPOLYSACCHARIDE BINDING PROTEIN; TOLL LIKE RECEPTOR 4; ACTA2 PROTEIN, HUMAN; ACTIN; ACUTE PHASE PROTEIN; CARRIER PROTEIN; LIPOPOLYSACCHARIDE-BINDING PROTEIN; MEMBRANE PROTEIN;

ADULT; ARTICLE; BILE DUCT; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ACTIVITY; FEMALE; HEPATIC PROGENITOR CELL; HEPATITIS; HUMAN; HUMAN TISSUE; HYPERTENSION; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; LIVER FIBROSIS; LIVER HISTOLOGY; MAJOR CLINICAL STUDY; MALE; NONALCOHOLIC FATTY LIVER; ORAL GLUCOSE TOLERANCE TEST; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; STELLATE CELL; BIOPSY; FLUORESCENT ANTIBODY TECHNIQUE; HISTOLOGY; INFLAMMATION; ITALY; LIVER; LIVER CIRRHOSIS; METABOLISM; MYOFIBROBLAST; NONPARAMETRIC TEST; PATHOPHYSIOLOGY; PORTAL VEIN;

ACTINS; ACUTE-PHASE PROTEINS; BIOPSY; CARRIER PROTEINS; FLUORESCENT ANTIBODY TECHNIQUE; HEPATIC STELLATE CELLS; HISTOLOGICAL TECHNIQUES; HUMANS; IMMUNOHISTOCHEMISTRY; INFLAMMATION; ITALY; KERATIN-7; LIVER; LIVER CIRRHOSIS; MEMBRANE GLYCOPROTEINS; MYOFIBROBLASTS; NON-ALCOHOLIC FATTY LIVER DISEASE; PORTAL SYSTEM; STATISTICS, NONPARAMETRIC; TOLL-LIKE RECEPTOR 4;

EID: 84921603955     PISSN: 14783223     EISSN: 14783231     Source Type: Journal    
DOI: 10.1111/liv.12531     Document Type: Article

References (41)

1. Szabo G, Bala S. Alcoholic liver disease and the gut-liver axis. World J Gastroenterol 2010; 16: 1321-9.
2. Yang SQ, Lin HZ, Lane MD, Clemens M, Diehl AM. Obesity increases sensitivity to endotoxin liver injury: implications for the pathogenesis of steatohepatitis. Proc Natl Acad Sci U S A 1997; 94: 2557-62.
3. Rivera CA, Adegboyega P, van Rooijen N, et al. Toll-like receptor-4 signaling and Kupffer cells play pivotal roles in the pathogenesis of non-alcoholic steatohepatitis. J Hepatol 2007; 47: 571-9.
4. Li Z, Yang S, Lin H, et al. Probiotics and antibodies to TNF inhibit inflammatory activity and improve nonalcoholic fatty liver disease. Hepatology 2003; 37: 343-50.
5. Frazier TH, DiBaise JK, McClain CJ. Gut microbiota, intestinal permeability, obesity-induced inflammation, and liver injury. JPEN J Parenter Enteral Nutr 2011; 35: 14S-20S.
6. Ruiz AG, Casafont F, Crespo J, et al. Lipopolysaccharide-binding protein plasma levels and liver TNF-alpha gene expression in obese patients: evidence for the potential role of endotoxin in the pathogenesis of non-alcoholic steatohepatitis. Obes Surg 2007; 17: 1374-80.
7. Van Bossuyt H, De Zanger RB, Wisse E. Cellular and subcellular distribution of injected lipopolysaccharide in rat liver and its inactivation by bile salts. J Hepatol 1988; 7: 325-37.
8. Mimura Y, Sakisaka S, Harada M, Sata M, Tanikawa K. Role of hepatocytes in direct clearance of lipopolysaccharide in rats. Gastroenterology 1995; 109: 1969-76.
9. Vespasiani-Gentilucci U, Carotti S, Onetti-Muda A, et al. Toll-like receptor-4 expression by hepatic progenitor cells and biliary epithelial cells in HCV-related chronic liver disease. Mod Pathol 2012; 25: 576-89.
10. Kleiner DE, Brunt EM, Van Natta M, et al. Design and validation of a histological scoring system for nonalcoholic fatty liver disease. Hepatology 2005; 41: 1313-21.
11. Ishak K, Baptista A, Bianchi L, et al. Histological grading and staging of chronic hepatitis. J Hepatol 1995; 22: 696-9.
12. Kleiner DE, Brunt EM. Nonalcoholic fatty liver disease: pathologic patterns and biopsy evaluation in clinical research. Semin Liver Dis 2012; 32: 3-13.
13. Brunt EM, Janney CG, Di Bisceglie AM, et al. Nonalcoholic steatohepatitis: a proposal for grading and staging the histological lesions. Am J Gastroenterol 1999; 94: 2467-74.
14. Gaudio E, Carpino G, Cardinale V, et al. New insights into liver stem cells. Dig Liver Dis 2009; 41: 455-62.
15. Spee B, Carpino G, Schotanus BA, et al. Characterisation of the liver progenitor cell niche in liver diseases: potential involvement of Wnt and Notch signalling. Gut 2010; 59: 247-57.
16. Turner R, Lozoya O, Wang Y, et al. Human hepatic stem cell and maturational liver lineage biology. Hepatology 2011; 53: 1035-45.
17. Cassiman D, Libbrecht L, Desmet V, et al. Hepatic stellate cell/myofibroblast subpopulations in fibrotic human and rat livers. J Hepatol 2002; 36: 200-9.
18. Schmitt-Graff A, Kruger S, Bochard F, et al. Modulation of alpha smooth muscle actin and desmin expression in perisinusoidal cells of normal and diseased human livers. Am J Pathol 1991; 138: 1233-42.
19. Clouston AD, Powell EE, Walsh MJ, et al. Fibrosis correlates with a ductular reaction in hepatitis C: roles of impaired replication, progenitor cells and steatosis. Hepatology 2005; 41: 809-18.
20. Roskams TA, Theise ND, Balabaud C, et al. Nomenclature of the finer branches of the biliary tree: canals, ductules, and ductular reactions in human livers. Hepatology 2004; 39: 1739-45.
21. White DL, Kanwal F, El-Serag HB. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012; 10: 1342-59.
22. Guzmán M, Castro J. Zonation of fatty acid metabolism in rat liver. Biochem J 1989; 264: 107-13.
23. Brunt EM, Kleiner DE, Wilson LA, et al. Portal chronic inflammation in nonalcoholic fatty liver disease (NAFLD): a histologic marker of advanced NAFLD. Clinicopathologic correlations from the nonalcoholic steatohepatitis clinical research network. Hepatology 2009; 49: 809-20.
24. Rakha EA, Adamson L, Bell E, et al. Portal inflammation is associated with advanced histological changes in alcoholic and non-alcoholic fatty liver disease. J Clin Pathol 2010; 63: 790-5.
25. Richardson MM, Jonsson JR, Powell EE, et al. Progressive fibrosis in nonalcoholic steatohepatitis: association with altered regeneration and a ductular reaction. Gastroenterology 2007; 133: 80-90.
26. Gadd VL, Skoien R, Powell EE, et al. The portal inflammatory infiltrate and ductular reaction in human non-alcoholic fatty liver disease. Hepatology 2014; 59: 1393-405.
27. Chiba M, Sasaki M, Kitamura S, et al. Participation of bile ductular cells in the pathological progression of non-alcoholic fatty liver disease. J Clin Pathol 2011; 64: 564-70.
28. Andreakos E, Foxwell B, Feldmann M. Is targeting Toll-like receptors and their signaling pathway a useful therapeutic approach to modulating cytokine-driven inflammation? Immunol Rev 2004; 202: 250-65.
29. Karrar A, Broome U, Södergren T, et al. Biliary epithelial cell antibodies link adaptive and innate immune responses in primary sclerosing cholangitis. Gastroenterology 2007; 132: 1504-14.
30. Wang A, Migita K, Ito M, et al. Hepatic expression of toll-like receptor 4 in primary biliary cirrhosis. J Autoimmun 2005; 25: 85-91.
31. Mueller T, Beutler C, Picó AH, et al. Enhanced innate immune responsiveness and intolerance to intestinal endotoxins in human biliary epithelial cells contributes to chronic cholangitis. Liver Int 2011; 31: 1574-88.
32. Harada K, Ohira S, Isse K, et al. Lipopolysaccharide activates nuclear factor-kappaB through toll-like receptors and related molecules in cultured biliary epithelial cells. Lab Invest 2003; 83: 1657-67.
33. Nagai Y, Garrett KP, Ohta S, et al. Toll-like receptors on hematopoietic progenitor cells stimulate innate immune system replenishment. Immunity 2006; 24: 801-12.
34. Pevsner-Fischer M, Morad V, Cohen-Sfady M, et al. Toll-like receptors and their ligands control mesenchymal stem cell functions. Blood 2007; 109: 1422-32.
35. Lee SH, Hong B, Sharabi A, et al. Embryonic stem cells and mammary luminal progenitors directly sense and respond to microbial products. Stem Cells 2009; 27: 1604-15.
36. Machida K, Tsukamoto H, Mkrtchyan H, et al. Toll-like receptor 4 mediates synergism between alcohol and HCV in hepatic oncogenesis involving stem cell marker Nanog. Proc Natl Acad Sci USA 2009; 106: 1548-53.
37. Lorenzini S, Bird TG, Boulter L, et al. Characterisation of a stereotypical cellular and extracellular adult liver progenitor cell niche in rodents and diseased human liver. Gut 2010; 59: 645-54.
38. Boulter L, Govaere O, Bird TG, et al. Macrophage-derived Wnt opposes Notch signaling to specify hepatic progenitor cell fate in chronic liver disease. Nat Med 2012; 18: 572-9.
39. Gadd VL, Melino M, Roy S, et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C. Liver Int 2013; 33: 569-79.
40. Seki E, De Minicis S, Osterreicher CH, et al. TLR4 enhances TGF-beta signaling and hepatic fibrosis. Nat Med 2007; 13: 1324-32.
41. Guo J, Loke J, Zheng F, et al. Functional linkage of cirrhosis-predictive single nucleotide polymorphisms of Toll-like receptor 4 to hepatic stellate cell responses. Hepatology 2009; 49: 960-8.